Comparative Pharmacology
Head-to-head clinical analysis: MIRAPEX ER versus PERGOLIDE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRAPEX ER versus PERGOLIDE MESYLATE.
MIRAPEX ER vs PERGOLIDE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ergot dopamine agonist with high affinity for D2 and D3 receptor subtypes; stimulates dopamine receptors in the striatum.
Ergoline-derived dopamine D2 receptor agonist; also activates D1 and D3 receptors, and has antagonist activity at α2-adrenergic and 5-HT2B receptors.
Oral, start 0.375 mg once daily, titrate weekly by 0.375 mg/dose to 1.5 mg once daily (immediate-release); ER: same total daily dose once daily.
0.05 mg orally once daily for first 2 days, then increase by 0.1-0.15 mg/day every 3 days over 12 days, then by 0.25 mg/day every 3 days until optimal response; usual therapeutic range 2-3 mg/day divided 3 times daily; maximum 5 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours in young healthy adults; prolonged to 16–40 hours in elderly (≥65 years) and up to 30 hours in moderate renal impairment (CrCl 20–50 mL/min).
Terminal elimination half-life: 15-27 hours (mean 21 hours); clinically relevant for once-daily dosing
Renal excretion of unchanged drug and metabolites: ~90% in urine (pramipexole: ~70% unchanged; N-desmethyl metabolite: ~20%). Fecal excretion: ~2%. Biliary elimination: minimal.
Renal: 50-60% as metabolites; Fecal: 40-50%; Biliary: minor (<5%)
Category C
Category C
Dopamine Agonist
Dopamine Agonist